세계의 유도만능줄기세포(iPS 세포) 제조 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2032년)

"Persistence Market Research provides an in-depth analysis of the global Induced Pluripotent Stem Cells (iPSCs) Production Market, offering insights into market dynamics, key growth drivers, challenges, and emerging trends. This comprehensive report equips stakeholders with detailed data and statistics to navigate the market landscape from 2024 to 2032.

The global iPSCs production market is projected to experience robust growth between 2024 and 2032, with an expected CAGR of 15.5% during this period. The market is anticipated to expand from an estimated value of USD 1.2 billion in 2024 to USD 2.9 billion by the end of 2032.

Key Insights:

• Estimated Market Value (2024): USD 1.2 Billion
• Projected Market Value (2032): USD 2.9 Billion
• Global Market Growth Rate (CAGR 2024 to 2032): 15.5%

iPSCs Production Market - Report Scope:

Induced pluripotent stem cells (iPSCs) are generated from adult cells reprogrammed to an embryonic stem cell-like state, offering immense potential for regenerative medicine, disease modeling, and drug discovery. The ability to derive patient-specific iPSCs holds promise for personalized medicine, driving the demand for iPSC production.

The report covers various aspects of the iPSCs production market, including advancements in reprogramming technologies, the increasing application of iPSCs in research and therapy, and the growing investment in stem cell research. It also examines regulatory frameworks and ethical considerations impacting market dynamics.

Market Growth Drivers:

The iPSCs production market is driven by the expanding field of regenerative medicine and the need for personalized therapeutic approaches. iPSCs offer a promising avenue for developing patient-specific treatments, addressing the limitations of traditional therapies. Additionally, advancements in gene editing technologies, such as CRISPR-Cas9, enhance the precision and efficiency of iPSC reprogramming, boosting market growth.

Increased funding and investment in stem cell research by government bodies, academic institutions, and private companies further propel the market. The rising prevalence of chronic diseases and the need for innovative treatments underscore the significance of iPSCs in drug discovery and development.

Market Restraints:

Despite the promising outlook, the iPSCs production market faces challenges. High production costs and technical complexities associated with iPSC generation and maintenance can hinder market growth. The risk of genetic mutations and tumorigenicity during the reprogramming process raises safety concerns, impacting clinical applications.

Ethical considerations related to stem cell research and the regulatory landscape also pose challenges. Stringent regulations and varying ethical standards across regions can limit market expansion. Additionally, the lack of standardized protocols for iPSC production and differentiation affects the reproducibility and reliability of research outcomes.

Market Opportunities:

The iPSCs production market presents numerous opportunities for innovation and expansion. Advancements in reprogramming technologies and the development of safer, more efficient methods for generating iPSCs are key areas of focus. The integration of artificial intelligence and machine learning in stem cell research offers potential for optimizing iPSC production and differentiation processes.

Emerging applications of iPSCs in organoid and tissue engineering, as well as their use in developing personalized drug screening platforms, present significant growth opportunities. Collaborations between academic institutions, research organizations, and biotechnology companies can drive innovation and accelerate the commercialization of iPSC-based therapies.

Competitive Landscape and Business Strategies:

Leading companies in the iPSCs production market include FUJIFILM Cellular Dynamics, Inc., Lonza Group Ltd., and Takara Bio Inc. These companies focus on product innovation, research and development, and strategic collaborations to maintain their competitive edge. FUJIFILM Cellular Dynamics is known for its high-quality iPSC lines, while Lonza Group emphasizes scalable production solutions. Takara Bio leverages its expertise in gene editing and cell culture technologies to offer comprehensive iPSC services.

Strategic partnerships, mergers, and acquisitions are commonly employed to expand market presence and access new technologies. Companies are also investing in clinical trials to demonstrate the safety and efficacy of iPSC-based therapies, fostering confidence among healthcare professionals and regulatory bodies.

Key Companies Profiled:

• FUJIFILM Cellular Dynamics, Inc.
• Lonza Group Ltd.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• Merck KGaA
• REPROCELL Inc.
• Stemcell Technologies Inc.
• Cellular Engineering Technologies Inc.
• Cynata Therapeutics Limited
• BrainXell, Inc.

iPSCs Production Market Segmentation:

By Product Type

• Instruments/Devices
• Automated Platforms
• Consumables & Kits
• Kits
• Others
• Services

By Process

• Manual
• Automated

By Workflow

• Reprogramming
• Cell Culture
• Cell Characterization/Analysis
• Engineering
• Others

By Application

• Drug Development and Discovery
• Regenerative Medicine
• Toxicology Studies
• Others

By Region

• North America
• Latin America
• Europe
• APAC
• MEA

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Summary of Statistics
• 1.3. Key Market Characteristics & Attributes
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage
• 2.2. Market Definition

3. Market Risks and Trends Assessment

• 3.1. Risk Assessment
  • 3.1.1. COVID-19 Crisis and Impact on Induced Pluripotent Stem Cells Production Market
  • 3.1.2. COVID-19 Impact Benchmark with Previous Crisis
  • 3.1.3. Impact on Market Value (US$ Bn)
  • 3.1.4. Assessment by Key Countries
  • 3.1.5. Assessment by Key Market Segments
  • 3.1.6. Action Points and Recommendation for Suppliers
• 3.2. Key Trends Impacting the Market
• 3.3. Formulation and Product Development Trends

4. Market Background

• 4.1. Induced Pluripotent Stem Cells Production Market, by Key Countries
• 4.2. Induced Pluripotent Stem Cells Production Market Opportunity Assessment (US$ Bn)
  • 4.2.1. Total Available Market
  • 4.2.2. Serviceable Addressable Market
  • 4.2.3. Serviceable Obtainable Market
• 4.3. Market Scenario Forecast
  • 4.3.1. Demand in optimistic Scenario
  • 4.3.2. Demand in Likely Scenario
  • 4.3.3. Demand in Conservative Scenario
• 4.4. Investment Feasibility Analysis
  • 4.4.1. Investment in Established Markets
    • 4.4.1.1. In Short Term
    • 4.4.1.2. In Long Term
  • 4.4.2. Investment in Emerging Markets
    • 4.4.2.1. In Short Term
    • 4.4.2.2. In Long Term
• 4.5. Forecast Factors - Relevance & Impact
  • 4.5.1. Top Companies Historical Growth
  • 4.5.2. Growth in Automation, By Country
  • 4.5.3. Induced Pluripotent Stem Cells Production Adoption Rate, By Country
• 4.6. Market Dynamics
  • 4.6.1. Market Driving Factors and Impact Assessment
  • 4.6.2. Prominent Market Challenges and Impact Assessment
  • 4.6.3. Induced Pluripotent Stem Cells Production Market Opportunities
  • 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

• 5.1. Manufacturers' Focus on Low Penetration High Growth Markets
• 5.2. Banking on with Segments High Incremental Opportunity
• 5.3. Peer Benchmarking

6. Global Induced Pluripotent Stem Cells Production Market Demand Analysis 2019-2023 and Forecast, 2024-2032

• 6.1. Historical Market Analysis, 2019-2023
• 6.2. Current and Future Market Projections, 2024-2032
• 6.3. Y-o-Y Growth Trend Analysis

7. Global Induced Pluripotent Stem Cells Production Market Value Analysis 2019-2023 and Forecast, 2024-2032

• 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Induced Pluripotent Stem Cells Production Market Analysis 2019-2023 and Forecast 2024-2032, By Product Type

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Bn) Analysis By Product Type, 2019-2023
• 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product Type, 2024-2032
  • 8.3.1. Consumables & Kits
    • 8.3.1.1. Media
    • 8.3.1.2. Kits
    • 8.3.1.3. Other Consumables & Kits
  • 8.3.2. Instruments/Devices
  • 8.3.3. Automated Platforms
  • 8.3.4. Services
• 8.4. Market Attractiveness Analysis By Product Type

9. Global Induced Pluripotent Stem Cells Production Market Analysis 2019-2023 and Forecast 2024-2032, By Process

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Bn) Analysis By Process, 2019-2023
• 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Process, 2024-2032
  • 9.3.1. Manual
  • 9.3.2. Automated
• 9.4. Market Attractiveness Analysis By Process

10. Global Induced Pluripotent Stem Cells Production Market Analysis 2019-2023 and Forecast 2024-2032, By Workflow

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Bn) Analysis By Workflow, 2019-2023
• 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Workflow, 2024-2032
  • 10.3.1. Reprogramming
  • 10.3.2. Cell Culture
  • 10.3.3. Cell Characterization/Analysis
  • 10.3.4. Engineering
  • 10.3.5. Other Workflows
• 10.4. Market Attractiveness Analysis By Workflow

11. Global Induced Pluripotent Stem Cells Production Market Analysis 2019-2023 and Forecast 2024-2032, By Application

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Bn) Analysis By Application, 2019-2023
• 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Application, 2024-2032
  • 11.3.1. Regenerative Medicine
  • 11.3.2. Drug Development and Discovery
  • 11.3.3. Toxicology Studies
  • 11.3.4. Other Applications
• 11.4. Market Attractiveness Analysis By Application

12. Global Induced Pluripotent Stem Cells Production Market Analysis 2019-2023 and Forecast 2024-2032, By Region

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
• 12.3. Current Market Size (US$ Bn) & Analysis and Forecast By Region, 2024-2032
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. Asia Pacific
  • 12.3.5. Middle East and Africa (MEA)
• 12.4. Market Attractiveness Analysis By Region

13. North America Induced Pluripotent Stem Cells Production Market Analysis 2019-2023 and Forecast 2024-2032

• 13.1. Introduction
• 13.2. Pricing Analysis
• 13.3. Historical Market Value (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 13.4. Market Value (US$ Bn) & Forecast By Market Taxonomy, 2024-2032
  • 13.4.1. By Country
    • 13.4.1.1. U.S.
    • 13.4.1.2. Canada
    • 13.4.1.3. Rest of North America
  • 13.4.2. By Product Type
  • 13.4.3. By Process
  • 13.4.4. By Application
  • 13.4.5. By Workflow
• 13.5. Market Attractiveness Analysis
  • 13.5.1. By Country
  • 13.5.2. By Product Type
  • 13.5.3. By Process
  • 13.5.4. By Application
  • 13.5.5. By Workflow

14. Latin America Induced Pluripotent Stem Cells Production Market Analysis 2019-2023 and Forecast 2024-2032

• 14.1. Introduction
• 14.2. Pricing Analysis
• 14.3. Historical Market Value (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.4. Market Value (US$ Bn) & Forecast By Market Taxonomy, 2024-2032
  • 14.4.1. By Country
    • 14.4.1.1. Brazil
    • 14.4.1.2. Mexico
    • 14.4.1.3. Rest of Latin America
  • 14.4.2. By Product Type
  • 14.4.3. By Process
  • 14.4.4. By Application
  • 14.4.5. By Workflow
• 14.5. Market Attractiveness Analysis
  • 14.5.1. By Country
  • 14.5.2. By Product Type
  • 14.5.3. By Process
  • 14.5.4. By Application
  • 14.5.5. By Workflow

15. Europe Induced Pluripotent Stem Cells Production Market Analysis 2019-2023 and Forecast 2024-2032

• 15.1. Introduction
• 15.2. Pricing Analysis
• 15.3. Historical Market Value (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 15.4. Market Value (US$ Bn) & Forecast By Market Taxonomy, 2024-2032
  • 15.4.1. By Country
    • 15.4.1.1. Germany
    • 15.4.1.2. France
    • 15.4.1.3. U.K.
    • 15.4.1.4. Italy
    • 15.4.1.5. Benelux
    • 15.4.1.6. Nordic Countries
    • 15.4.1.7. Rest of Europe
  • 15.4.2. By Product Type
  • 15.4.3. By Process
  • 15.4.4. By Application
  • 15.4.5. By Workflow
• 15.5. Market Attractiveness Analysis
  • 15.5.1. By Country
  • 15.5.2. By Product Type
  • 15.5.3. By Process
  • 15.5.4. By Application
  • 15.5.5. By Workflow

16. Asia Pacific Induced Pluripotent Stem Cells Production Market Analysis 2019-2023 and Forecast 2024-2032

• 16.1. Introduction
• 16.2. Pricing Analysis
• 16.3. Historical Market Value (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 16.4. Market Value (US$ Bn) & Forecast By Market Taxonomy, 2024-2032
  • 16.4.1. By Country
    • 16.4.1.1. China
    • 16.4.1.2. Japan
    • 16.4.1.3. South Korea
    • 16.4.1.4. Rest of Asia Pacific
  • 16.4.2. By Product Type
  • 16.4.3. By Process
  • 16.4.4. By Application
  • 16.4.5. By Workflow
• 16.5. Market Attractiveness Analysis
  • 16.5.1. By Country
  • 16.5.2. By Product Type
  • 16.5.3. By Process
  • 16.5.4. By Application
  • 16.5.5. By Workflow

17. Middle East and Africa Induced Pluripotent Stem Cells Production Market Analysis 2019-2023 and Forecast 2024-2032

• 17.1. Introduction
• 17.2. Pricing Analysis
• 17.3. Historical Market Value (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 17.4. Market Value (US$ Bn) & Forecast By Market Taxonomy, 2024-2032
  • 17.4.1. By Country
    • 17.4.1.1. GCC Countries
    • 17.4.1.2. South Africa
    • 17.4.1.3. Turkey
    • 17.4.1.4. Rest of Middle East and Africa
  • 17.4.2. By Product Type
  • 17.4.3. By Process
  • 17.4.4. By Application
  • 17.4.5. By Workflow
• 17.5. Market Attractiveness Analysis
  • 17.5.1. By Country
  • 17.5.2. By Product Type
  • 17.5.3. By Process
  • 17.5.4. By Application
  • 17.5.5. By Workflow

18. Key Countries Induced Pluripotent Stem Cells Production Market Analysis 2019-2023 and Forecast 2024-2032

• 18.1. Introduction
  • 18.1.1. Market Value Proportion Analysis, By Key Countries
  • 18.1.2. Global Vs. Country Growth Comparison
• 18.2. US Induced Pluripotent Stem Cells Production Market Analysis
  • 18.2.1. Value Proportion Analysis by Market Taxonomy
  • 18.2.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.2.2.1. By Product Type
    • 18.2.2.2. By Process
    • 18.2.2.3. By Application
    • 18.2.2.4. By Workflow
• 18.3. Canada Induced Pluripotent Stem Cells Production Market Analysis
  • 18.3.1. Value Proportion Analysis by Market Taxonomy
  • 18.3.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.3.2.1. By Product Type
    • 18.3.2.2. By Process
    • 18.3.2.3. By Application
    • 18.3.2.4. By Workflow
• 18.4. Mexico Induced Pluripotent Stem Cells Production Market Analysis
  • 18.4.1. Value Proportion Analysis by Market Taxonomy
  • 18.4.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.4.2.1. By Product Type
    • 18.4.2.2. By Process
    • 18.4.2.3. By Application
    • 18.4.2.4. By Workflow
• 18.5. Brazil Induced Pluripotent Stem Cells Production Market Analysis
  • 18.5.1. Value Proportion Analysis by Market Taxonomy
  • 18.5.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.5.2.1. By Product Type
    • 18.5.2.2. By Process
    • 18.5.2.3. By Application
    • 18.5.2.4. By Workflow
• 18.6. Germany Induced Pluripotent Stem Cells Production Market Analysis
  • 18.6.1. Value Proportion Analysis by Market Taxonomy
  • 18.6.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.6.2.1. By Product Type
    • 18.6.2.2. By Process
    • 18.6.2.3. By Application
    • 18.6.2.4. By Workflow
• 18.7. France Induced Pluripotent Stem Cells Production Market Analysis
  • 18.7.1. Value Proportion Analysis by Market Taxonomy
  • 18.7.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.7.2.1. By Product Type
    • 18.7.2.2. By Process
    • 18.7.2.3. By Application
    • 18.7.2.4. By Workflow
• 18.8. Italy Induced Pluripotent Stem Cells Production Market Analysis
  • 18.8.1. Value Proportion Analysis by Market Taxonomy
  • 18.8.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.8.2.1. By Product Type
    • 18.8.2.2. By Process
    • 18.8.2.3. By Application
    • 18.8.2.4. By Workflow
• 18.9. BENELUX Induced Pluripotent Stem Cells Production Market Analysis
  • 18.9.1. Value Proportion Analysis by Market Taxonomy
  • 18.9.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.9.2.1. By Product Type
    • 18.9.2.2. By Process
    • 18.9.2.3. By Application
    • 18.9.2.4. By Workflow
• 18.10. UK Induced Pluripotent Stem Cells Production Market Analysis
  • 18.10.1. Value Proportion Analysis by Market Taxonomy
  • 18.10.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.10.2.1. By Product Type
    • 18.10.2.2. By Process
    • 18.10.2.3. By Application
    • 18.10.2.4. By Workflow
• 18.11. Nordic Countries Induced Pluripotent Stem Cells Production Market Analysis
  • 18.11.1. Value Proportion Analysis by Market Taxonomy
  • 18.11.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.11.2.1. By Product Type
    • 18.11.2.2. By Process
    • 18.11.2.3. By Application
    • 18.11.2.4. By Workflow
• 18.12. China Induced Pluripotent Stem Cells Production Market Analysis
  • 18.12.1. Value Proportion Analysis by Market Taxonomy
  • 18.12.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.12.2.1. By Product Type
    • 18.12.2.2. By Process
    • 18.12.2.3. By Application
    • 18.12.2.4. By Workflow
• 18.13. Japan Induced Pluripotent Stem Cells Production Market Analysis
  • 18.13.1. Value Proportion Analysis by Market Taxonomy
  • 18.13.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.13.2.1. By Product Type
    • 18.13.2.2. By Process
    • 18.13.2.3. By Application
    • 18.13.2.4. By Workflow
• 18.14. South Korea Induced Pluripotent Stem Cells Production Market Analysis
  • 18.14.1. Value Proportion Analysis by Market Taxonomy
  • 18.14.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.14.2.1. By Product Type
    • 18.14.2.2. By Process
    • 18.14.2.3. By Application
    • 18.14.2.4. By Workflow
• 18.15. GCC Countries Induced Pluripotent Stem Cells Production Market Analysis
  • 18.15.1. Value Proportion Analysis by Market Taxonomy
  • 18.15.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.15.2.1. By Product Type
    • 18.15.2.2. By Process
    • 18.15.2.3. By Application
    • 18.15.2.4. By Workflow
• 18.16. South Africa Induced Pluripotent Stem Cells Production Market Analysis
  • 18.16.1. Value Proportion Analysis by Market Taxonomy
  • 18.16.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.16.2.1. By Product Type
    • 18.16.2.2. By Process
    • 18.16.2.3. By Application
    • 18.16.2.4. By Workflow
• 18.17. Turkey Induced Pluripotent Stem Cells Production Market Analysis
  • 18.17.1. Value Proportion Analysis by Market Taxonomy
  • 18.17.2. Value Analysis and Forecast by Market Taxonomy, 2019-2032
    • 18.17.2.1. By Product Type
    • 18.17.2.2. By Process
    • 18.17.2.3. By Application
    • 18.17.2.4. By Workflow
  • 18.17.3. Competition Landscape and Player Concentration in the Country

19. Market Structure Analysis

• 19.1. Market Analysis by Tier of Companies
• 19.2. Market Concentration
• 19.3. Market Share Analysis of Top Players
• 19.4. Market Presence Analysis
  • 19.4.1. By Regional footprint of Players
  • 19.4.2. Product footprint by Players

20. Competition Analysis

• 20.1. Competition Dashboard
• 20.2. Competition Benchmarking
• 20.3. Competition Deep Dive
  • 20.3.1. LONZA
    • 20.3.1.1. Product Portfolio
    • 20.3.1.2. Key Strategies
    • 20.3.1.3. Key Developments
  • 20.3.2. AXOL BIOSCIENCES LTD
    • 20.3.2.1. Product Portfolio
    • 20.3.2.2. Key Strategies
    • 20.3.2.3. Key Developments
  • 20.3.3. EVOTEC
    • 20.3.3.1. Product Portfolio
    • 20.3.3.2. Key Strategies
    • 20.3.3.3. Key Developments
  • 20.3.4. HITACHI LTD
    • 20.3.4.1. Product Portfolio
    • 20.3.4.2. Key Strategies
    • 20.3.4.3. Key Developments
  • 20.3.5. REPROCELL INC
    • 20.3.5.1. Product Portfolio
    • 20.3.5.2. Key Strategies
    • 20.3.5.3. Key Developments
  • 20.3.6. FATE THERAPEUTICS.
    • 20.3.6.1. Product Portfolio
    • 20.3.6.2. Key Strategies
    • 20.3.6.3. Key Developments
  • 20.3.7. THERMO FISHER SCIENTIFIC, INC.
    • 20.3.7.1. Product Portfolio
    • 20.3.7.2. Key Strategies
    • 20.3.7.3. Key Developments
  • 20.3.8. MERCK KGAA (MILLIPORESIGMA)
    • 20.3.8.1. Product Portfolio
    • 20.3.8.2. Key Strategies
    • 20.3.8.3. Key Developments
  • 20.3.9. STEMCELLFACTORY III
    • 20.3.9.1. Product Portfolio
    • 20.3.9.2. Key Strategies
    • 20.3.9.3. Key Developments
  • 20.3.10. APPLIED STEMCELL INC.
    • 20.3.10.1. Product Portfolio
    • 20.3.10.2. Key Strategies
    • 20.3.10.3. Key Developments

21. Assumptions and Acronyms Used

22. Research Methodology